{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T03:05:24Z","timestamp":1789700724499,"version":"4.0.1"},"reference-count":10,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/eurjpc\/zwag485","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:24:30Z","timestamp":1788780270000},"source":"Crossref","is-referenced-by-count":0,"title":["Zodasiran in mixed hyperlipidaemia: durable lipid lowering, cardiovascular benefit unresolved"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6261-9445","authenticated-orcid":false,"given":"Fariba","family":"Ahmadizar","sequence":"first","affiliation":[{"name":"Department of General Practice, Amsterdam University Medical Center , Medical Faculty Building, Van der Boechorststraat 7, 1081 BT, Amsterdam ,","place":["The Netherlands"]},{"name":"Department of Epidemiology and Data Sciences, Amsterdam University Medical Center , Medical Faculty Building, Van der Boechorststraat 7, 1081 BT, Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam Public Health Research Institute , Medical Faculty Building, Van der Boechorststraat 7, 1081 BT, Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Hollander","sequence":"additional","affiliation":[{"name":"Department of General Practice, Amsterdam University Medical Center , Medical Faculty Building, Van der Boechorststraat 7, 1081 BT, Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam Public Health Research Institute , Medical Faculty Building, Van der Boechorststraat 7, 1081 BT, Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"2026091722361952500_zwag485-B1","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwag376","article-title":"Longer-term efficacy and safety of zodasiran in patients with mixed hyperlipidaemia","author":"Rosenson","year":"2026","journal-title":"Eur J Prev Cardiol"},{"key":"2026091722361952500_zwag485-B2","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N Engl J Med"},{"key":"2026091722361952500_zwag485-B3","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies\u2014a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"2026091722361952500_zwag485-B4","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1093\/eurheartj\/ehae258","article-title":"Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention","volume":"45","author":"Sniderman","year":"2024","journal-title":"Eur Heart J"},{"key":"2026091722361952500_zwag485-B5","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"2026091722361952500_zwag485-B6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2026091722361952500_zwag485-B7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N Engl J Med"},{"key":"2026091722361952500_zwag485-B8","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-026-04307-8","article-title":"Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial","volume":"32","author":"Watts","year":"2026","journal-title":"Nat Med"},{"key":"2026091722361952500_zwag485-B9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-8587(25)00290-6","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial","volume":"14","author":"Raal","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026091722361952500_zwag485-B10","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag485\/70996808\/zwag485.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag485\/70996808\/zwag485.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:36:22Z","timestamp":1789698982000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article\/doi\/10.1093\/eurjpc\/zwag485\/8788011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":10,"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwag485","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"zwag485"}}